Your pacemaker's data is yours—now Congress is making it official

What it does

This bill requires medical device manufacturers to give patients access to their own health data recorded by implanted or remote-monitoring devices (like pacemakers, glucose monitors, or cardiac monitors) when patients request it. The data must be provided in a patient-friendly format, and manufacturers must publicly disclose what data their devices collect and how they use it.

Why we flagged it

The bill's core mechanism is straightforward: it mandates patient access to personal health data from medical devices and requires manufacturers to disclose data practices. This is a transparency and patient-rights measure, not a market intervention or subsidy.

What the text implies

• Manufacturers may face operational costs to implement data-access systems and format conversion, which could be passed to consumers via device pricing or insurance premiums.
• The bill's reliance on FDA regulation (rather than statutory specificity) means implementation details and enforcement timelines remain uncertain until rules are issued.
• Public disclosure of data types and usage practices may expose competitive information about device capabilities, potentially benefiting competitors or enabling reverse-engineering.
• Patients gaining direct access to raw device data (e.g., pacemaker rhythms, glucose readings) without clinical interpretation could lead to misunderstanding or unnecessary medical consultation.

Who it affects

Patients gain direct access to their own medical data and transparency about what devices collect, enabling better health decisions and informed consent. Manufacturers retain exceptions for truly inaccessible data and proprietary information, balancing patient rights with legitimate business interests.

Who stands to gain

• health data analytics companies
• patient advocacy organizations
• electronic health record (EHR) vendors

Named in the bill

FDA (Food and Drug Administration), medical device manufacturers, pacemaker manufacturers, remote monitoring device makers, Federal Food, Drug, and Cosmetic Act

Where it stands

• Nov 18, 2025 — Introduced · Congress.gov: “Introduced in House”
• Nov 18, 2025 — Referred to House Committee on Energy and Commerce · Congress.gov: “Referred to the House Committee on Energy and Commerce”

Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.